ADVAIR HFA
ICSLABA MDI
Fluticasone propionate / Salmeterol · GlaxoSmithKline
Active Medication & Mechanism
- Fluticasone propionate ICS45 mcg, 115 mcg, or 230 mcg per actuation
Synthetic corticosteroid with potent anti-inflammatory activity. Inhibits multiple cell types and mediators involved in airway inflammation.
- Salmeterol xinafoate LABA21 mcg per actuation
Long-acting beta2-adrenergic agonist. Produces prolonged bronchodilation (≥12 hours) via beta2-receptor stimulation on airway smooth muscle.
FDA-Approved Dosing by Indication
// approval varies by strength + age Asthma
3/4 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 45/21 mcg | Patients ≥12 years | 2 inhalations twice daily (morning and evening, ~12 hours apart) For patients not adequately controlled on low-dose ICS or whose disease severity warrants initiation with two maintenance therapies. | 180/84 mcg | FDA Approved |
| 115/21 mcg | Patients ≥12 years | 2 inhalations twice daily For patients not adequately controlled on medium-dose ICS. | 460/84 mcg | FDA Approved |
| 230/21 mcg | Patients ≥12 years | 2 inhalations twice daily For patients not adequately controlled on high-dose ICS. | 920/84 mcg | FDA Approved |
| Any strength | Acute bronchospasm | — | — | Not Approved Not a rescue inhaler. Use a SABA for acute symptoms. |
COPD
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Adults | — | — | Not Approved Advair HFA is NOT indicated for COPD. Use Advair Diskus 250/50 for COPD. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not indicated for acute bronchospasm. Use a SABA (e.g., albuterol). |